Price T Rowe Associates Inc. MD Trims Stock Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Price T Rowe Associates Inc. MD cut its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 12.1% during the 4th quarter, Holdings Channel.com reports. The firm owned 1,104,037 shares of the medical equipment provider’s stock after selling 151,611 shares during the quarter. Price T Rowe Associates Inc. MD’s holdings in Lantheus were worth $98,769,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in LNTH. Wilmington Savings Fund Society FSB bought a new stake in shares of Lantheus in the third quarter worth $25,000. Kestra Investment Management LLC acquired a new position in Lantheus during the 4th quarter worth $27,000. Summit Securities Group LLC bought a new stake in shares of Lantheus in the 4th quarter worth about $37,000. UMB Bank n.a. raised its stake in shares of Lantheus by 31.5% in the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock valued at $50,000 after purchasing an additional 134 shares in the last quarter. Finally, World Investment Advisors LLC acquired a new position in Lantheus in the third quarter worth about $60,000. 99.06% of the stock is owned by institutional investors and hedge funds.

Lantheus Stock Performance

LNTH stock opened at $101.77 on Monday. Lantheus Holdings, Inc. has a 1 year low of $65.76 and a 1 year high of $126.89. The stock has a market capitalization of $6.97 billion, a price-to-earnings ratio of 16.93 and a beta of 0.20. The stock’s fifty day moving average is $97.37 and its two-hundred day moving average is $95.14.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.23). The firm had revenue of $391.11 million during the quarter, compared to analyst estimates of $376.61 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. As a group, analysts predict that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have issued reports on LNTH shares. Truist Financial upped their price objective on Lantheus from $120.00 to $127.00 and gave the company a “buy” rating in a research note on Thursday, February 27th. JMP Securities restated a “market outperform” rating and set a $112.00 price objective on shares of Lantheus in a research note on Tuesday, January 14th. Finally, B. Riley lowered their target price on shares of Lantheus from $127.00 to $122.00 and set a “buy” rating for the company in a research note on Friday, March 21st. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $129.43.

Insider Activity

In other news, Director Mary Anne Heino sold 53,107 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the sale, the director now directly owns 440,399 shares of the company’s stock, valued at approximately $41,551,645.65. This represents a 10.76 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the transaction, the chief financial officer now owns 113,860 shares in the company, valued at $11,445,207.20. This represents a 8.07 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 63,109 shares of company stock valued at $6,016,046. Insiders own 1.50% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.